About Us
EXECUTIVE TEAM
Founder and President
Haiyan Fu
Haiyan Fu is the founder and the President of NeuroGT, Inc. She has over 2 decades of experience in AAV-based gene therapy research and development treating neuropathic lysosomal storage diseases. Her pioneering research has led to four IND approvals for systemic gene replacement therapy using trans-blood-brain-barrier neurotropic AAV9 vectors. With extensive experience in neurodegenerative disease models, translational medicine, and therapeutic development, Dr. Fu has dedicated her career to advancing life-saving gene therapies to treat children with devastating Mucopolysaccharidoses (MPS) disorders. She was trained in medicine, and also holds a MS in medical microbiology and a PhD in virology.
Chief Scientific Officer
Douglas McCarty
Douglas McCarty joined the company as the Chief Scientific Officer. He is a leading scientist in AAV gene therapy development, with over 35 years of research experience in AAV biology, vector engineering, vector production, preclinical research, and translational gene therapy. He is the inventor of the self-complementary AAV vector. His work has been instrumental in the development of AAV9-based gene delivery for rare genetic and neurodegenerative diseases, and led multiple IND-enabling studies. He has played a key role in the development of gene therapies designed to cross the blood-brain barrier (BBB), addressing the challenges of targeted gene delivery and long-term therapeutic efficacy. Dr. McCarty has held key positions in academia and biotech, driving the advancement of transformative gene therapies. He received a PhD in Molecular Biology from University of Florida
BOARD OF DIRECTORS
Founder and President
Haiyan Fu
Haiyan Fu is the founder and the President of NeuroGT, Inc. She has over 2 decades of experience in AAV-based gene therapy research and development treating neuropathic lysosomal storage diseases. Her pioneering research has led to four IND approvals for systemic gene replacement therapy using trans-blood-brain-barrier neurotropic AAV9 vectors. With extensive experience in neurodegenerative disease models, translational medicine, and therapeutic development, Dr. Fu has dedicated her career to advancing life-saving gene therapies to treat children with devastating Mucopolysaccharidoses (MPS) disorders. She was trained in medicine, and also holds a MS in medical microbiology and a PhD in virology.
Co-founder
Xiaomei Li Reckford
Xiaomei Li Reckford is the co-founder of the company. She has over 25 years experience in the pharmaceutical, biotech and CRO industries. She advises biotech, pharmaceutical, medical device, and diagnostic start-up companies to achieve regulatory and commercial goals in the United States and Asia. She served as Quintiles CEO of the Greater China region (PR China, Hong Kong, Taiwan) and Vice President for China Development and Global sales and Customer management. Prior to joining Quintiles, she was head of Asia Operations for PharmaResearch Corp, a North Carolina-based contract research organization. She was the founder of a regulatory consulting firm, Exelar China Ltd. She received a PhD in Pharmacology from University of North Carolina at Chapel Hill.